Publications by authors named "Tonya A Schneidereith"

Background: Artificial intelligence (AI) offers exciting possibilities; however, AI is a double-edged sword. The adoption of this technology offers many benefits but also presents risks to academic integrity and appropriately prepared graduates. Many of today's nurse educators are from generations that are unlikely to possess an understanding of AI.

View Article and Find Full Text PDF

Aim: This longitudinal study identified changes in safe medication administration behaviors in a single cohort of students followed over four semesters of nursing school.

Background: Over 40% of a nurse's shift is dedicated to the processes of medication administration, placing them in a position to interrupt costly medication errors. Yet, despite efforts to decrease medication errors, including electronic medical records, smart pumps, and standardized processes, 5% of hospitalized patients experience adverse drug events and the sequela costs billions of dollars annually.

View Article and Find Full Text PDF

Failure to ensure organizational readiness for curricular integration of simulation can result in a costly and ineffective simulation program. Organizational leaders who are aware of the principles of changemaker leadership and specific operational considerations are best positioned to ensure a quality simulation program. To assist these leaders, this article provides practical information derived from dissection of the Standard of Best Practice: Simulation : Operations, including topics of strategic planning, financial resources, expert personnel, resource management systems, policies and procedures, and systems integration.

View Article and Find Full Text PDF

The Centers for Disease Control and Prevention recognizes adverse drug events as a serious public health problem. Nurses routinely administer patient medications and must be safe when delivering care. Typically, students are taught the traditional rights method (RM) of safe medication administration in the skills laboratory and through the use of high-fidelity simulation scenarios.

View Article and Find Full Text PDF

The beta-chain hemoglobinopathies affect the beta-globin gene on chromosome 11 and comprise some of the most prevalent genetic disorders in humans, including sickle cell disease (SCD) and beta-thalassemia. The mutations associated with these diseases cause various symptoms and degrees of severity. Extensive research has sought to identify physiologic and genetic factors responsible for these variations, including the role of fetal hemoglobin (HbF) and its importance in the alleviation of symptoms.

View Article and Find Full Text PDF

Objective: In vivo, several drugs have been shown to increase fetal hemoglobin (HbF), including 5-azacytidine (AZA), sodium butyrate (SB), and hydroxyurea (HU). Studies in K562 cells suggest that cyclic guanosine monophosphate (cGMP) is required for HbF induction; however, the role of cyclic nucleotides in HbF induction in primary erythroid cultures has not been established.

Methods: CD34-selected peripheral blood monocytes cultured in a semi-solid serum-free system that mimics in vivo F-cell production are utilized to explore the role of cyclic adenosine monophosphate (cAMP) and cGMP in HbF induction in response to HU, AZA, and SB.

View Article and Find Full Text PDF